PS1

PS1 is a small molecule drug identified as an inhibitor of protein disulfide isomerase a4 (Pdia4). It has demonstrated pharmacological activity in preclinical models of diabetes, specifically by reducing β-cell death and dysfunction in db/db mice. Mechanistically, PS1 inhibits Pdia4 enzymatic activity, leading to reduced reactive oxygen species (ROS) production and improved insulin secretion and cell survival in pancreatic β-cells. The drug also disrupts the interaction between Pdia4 and other proteins involved in oxidative stress pathways (Ndufs3 and p22), contributing to its protective effects against hyperglycemia and diabetes-related β-cell pathogenesis[5]. Early clinical studies have evaluated the safety, pharmacokinetics, and food effect of oral PS1 tablets in healthy volunteers[2][6].

Other names

Phenylthiazolyl-1,3,5-triazine derivative PS1